查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1425156

促血红细胞生长素製剂市场－2024年至2029年预测

Erythropoietin Drugs Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 143 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2022年促血红细胞生长素药品市值为138.03亿美元。

促血红细胞生长素製剂用于治疗贫血，其特征是红血球数量减少。促血红细胞生长素生成素刺激剂 (ESA) 是促促血红细胞生长素的重组形式，透过细胞培养中的重组 DNA 技术以药理方式产生。 ESA 包括红血球生成素α、Darbepoetin和甲氧基聚乙二醇-红血球生成素生成素β。 pO2 越低，EPO 的形成越明显。当红血球生成减弱时，最常使用 ESA。由于 EPO 可以增加肌肉的氧气供应，因此有些运动员不当地使用 EPO 药物来提高表现。然而，使用 EPO 製剂也会带来严重的健康风险。

介绍

促血红细胞生长素製剂市场是一个不断成长的市场，涉及促血红细胞生长素兴奋剂（ESA）的生产和分销。 ESA是促促血红细胞生长素的重组製剂，透过细胞培养中的重组DNA技术在药理上产生。该市场是由贫血发病率上升（特别是在人口老化中）以及对生物相似药的需求不断增长所推动的。市场可以按药物类别、产品、应用和地区进行细分。亚太地区主导全球促血红细胞生长素药物市场。促血红细胞生长素药物市场的主要企业包括 Mayo Clinic、Weefsel Pharma、Trumac Healthcare 和 Incepta Pharmaceuticals Ltd。

促进因素

  • 贫血发生率增加： 促进因素： 贫血发生率增加： 虚弱的普遍存在，特别是在老年人群中，正在推动对促促血红细胞生长素製剂的需求不断增加。随着世界各地社会中老年人比例的增加，采取有效的医疗干预措施来解决与老龄化相关的病理的必要性变得越来越明显。促血红细胞生长素是一种糖蛋白激素，在促进骨髓中红血球的产生方面发挥着至关重要的作用。
  • 生物相似药需求不断增加：促血红细胞生长素产品的市场开拓呈现出生物相似药发展的模式。这是因为需要降低医疗成本并使患者获得这些药物。
  • 增加研发活动：促促血红细胞生长素製剂领域创新研发活动的进展将推动新药和治疗方法的开发，并推动市场发展。
  • 新兴市场的采用率不断提高：恶性生长、晚期肾病变（CKD）和爱滋病毒等永久性疾病在发展中业务领域的发病率呈上升趋势，使得促促血红细胞生长素素製剂在这些业务领域更受欢迎。我们正在推动对
  • 专利保护：随着许可证的获得，促血红细胞生长素（一种生技药品）很可能在试验期内主导市场。

主要企业提供的产品：

  • 梅奥诊所提供贫血治疗，例如红血球生成素素、Darbepoetin和甲氧基聚乙二醇-红血球生成素生成素β。
  • Weefsel Pharma 的促血红细胞生长素生成素注射是一种治疗肾损伤或化疗引起的贫血的药物。

促血红细胞生长素製剂市场中肾功能不全细分市场显着成长：

由于末期肾功能衰竭治疗、化疗和抗逆转录病毒治疗引起的贫血增加，预计促促血红细胞生长素製剂市场在未来几年将稳定成长。肾臟病细分市场（末期肾臟病和透析）在 2020 年占据了很大份额，预计在预测期内将保持强劲的成长轨迹。癌症、慢性肾臟病(CKD) 和爱滋病毒等慢性疾病的盛行率不断上升，刺激了对促血红细胞生长素产品的需求。但随着2018年促红血球促血红细胞生长素（EPO）生物相似药登陆美国市场、Aranesp在美国的专利到期、价格下跌以及HIF脯氨酰羟化酶抑製剂的上市等，替代产品的开拓正在减缓促促血红细胞生长素製剂市场的成长。由于促血红细胞生长素产品（生物製药）的专利仍然有效，预计促血红细胞生长素产品领域在预测期内将保持其主导地位。

预计亚太地区将在促血红细胞生长素製剂市场中占据主要份额：

由于人口快速增长和癌症和慢性肾臟病（CKD）等慢性疾病的高盛行率，预计亚太地区将占据促红血球生成促血红细胞生长素製剂市场的主要份额。该地区是促促血红细胞生长素发展前景广阔的市场，大部分促血红细胞生长素原创企业都集中在亚太市场。印度和中国是主要的促血红细胞生长素生物相似药市场，该地区在生物相似药产业中占据最大份额，这些地区的主要製造商开拓新兴国家生产生物相似药。亚太地区的大多数生物相似药製造商有能力以比创新产品低 25-40% 的价格推出促促血红细胞生长素生物相似药。由于促血红细胞生长素素的开发较少，亚太和拉美地区为促血红细胞生长素製造商提供了充满希望的成长机会。

主要进展：

  • 2020年6月，GlaxoSmithKline Plc公司（GSK）宣布推出口服缺氧诱导因子脯胺酸氧化酵素抑制剂（HIF-PHI）Dubroc（daprodustat），用于治疗慢性肾臟病（CKD）相关贫血，并获得药品核准。在日本。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 调查过程

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析

第五章促促血红细胞生长素製剂市场：依类型

  • 介绍
  • 生技药品
  • 生物相似药

第六章促促血红细胞生长素製剂市场：副产品

  • 介绍
  • 促血红细胞生长素
  • Darbepoetin法

第七章促促血红细胞生长素製剂市场：依应用分类

  • 介绍
  • 癌症
  • 肾臟疾病
  • 神经病学
  • 其他的

第八章促促血红细胞生长素製剂市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作

第十章 公司简介

  • Mayo Clinic
  • Weefsel Pharma
  • Trumac Healthcare
  • Incepta Pharmaceuticals Ltd.
  • FosunPharma
  • Rewine Pharmaceuticals
  • Kyowa Kirin
  • Mircera
  • ACRO Biosystems
  • Fierce Pharma
简介目录
Product Code: KSI061616114

The erythropoietin drugs market was valued at US$13.803 billion in 2022.

Erythropoietin drugs are used to treat anemia, which is a condition characterized by a low number of red blood cells. The erythropoietin stimulating agents (ESAs) are recombinant versions of erythropoietin produced pharmacologically via recombinant DNA technology in cell cultures. ESAs include epoetin alfa, darbepoetin, and methoxy polyethylene glycol-epoetin beta. The lower the pO2, the more prominent the creation of EPO. ESAs are for the most part shown in conditions where there is debilitated red platelet creation. Some athletes improperly use EPO drugs to boost their performance because EPO increases the availability of oxygen to their muscles. However, the use of EPO drugs can have serious health consequences as well.

Introduction:

The erythropoietin drugs market is a growing market that deals with the production and distribution of erythropoietin-stimulating agents (ESAs). ESAs are recombinant versions of erythropoietin produced pharmacologically via recombinant DNA technology in cell cultures. The market is driven by the increasing incidence of anaemia, particularly in the ageing population, and the growing demand for biosimilars. The market can be segmented based on drug class, product, application, and geography. Asia Pacific dominates the global erythropoietin drugs market. Key players operating in the erythropoietin drugs market include Mayo Clinic, Weefsel Pharma, Trumac Healthcare, and Incepta Pharmaceuticals Ltd.

Drivers:

  • Increasing incidence of anemia: The increasing prevalence of frailty, particularly among the aging demographic, has spurred a heightened demand for erythropoietin drugs. As societies around the world witness a growing proportion of elderly individuals, the need for effective medical interventions to address age-related conditions becomes more pronounced. Erythropoietin, a glycoprotein hormone, plays a pivotal role in stimulating the production of red blood cells in the bone marrow.
  • Growing demand for biosimilars: The market for erythropoietin drugs is seeing a developing pattern of biosimilars, which are less expensive options in contrast to marked drugs. This is driven by the need to decrease medical care costs and further develop admittance to these medications for patients.
  • Increasing research and development activities: The developing innovative work (Research and Development) exercises in the field of erythropoietin drugs are supposed to prompt the advancement of new medications and treatments, which will drive market development.
  • Growing adoption in emerging markets: The rising commonness of persistent sicknesses like malignant growth, ongoing kidney illness (CKD), and HIV in developing business sectors is driving the reception of erythropoietin drugs in these business sectors. This is supposed to help the market development before long.
  • Patents being protected: The biologics erythropoietin portion is supposed to rule the market during the gauge time frame, this is because of licenses being secured.

Products offered by key companies:

  • Mayo Clinic offers a range of erythropoietin drugs to treat anemia, including epoetin alfa, darbepoetin, and methoxy polyethylene glycol-epoetin beta. The clinic also provides comprehensive care for patients with anaemia, including diagnosis, treatment, and follow-up care.
  • Weefsel Pharma's erythropoietin injection is a treatment for anemia caused by kidney disorders and chemotherapy.

Prominent growth in the renal disorders segment within the erythropoietin drugs market:

The erythropoietin drug market is expected to grow steadily in the coming years, driven by the increasing prevalence of anemia caused by end-stage renal disease treatment, chemotherapy, and antiretroviral therapy. The kidney disorders segment (ESRD and dialysis) accounted for a significant share in 2020 and is expected to maintain a strong growth trajectory during the forecast period. The rising incidence of chronic diseases such as cancer, chronic kidney disease (CKD), and HIV is fueling the demand for erythropoietin drugs. However, the introduction of biosimilar erythropoietin (EPO) in the US market in 2018, the impending patent expiry of Aranesp in 2024 in the US, declining prices, and the development of alternative products such as HIF prolyl-hydroxylase inhibitors are moderating the growth of the erythropoietin drugs market. The biologics erythropoietin segment is expected to remain dominant during the forecast period, as patents for these drugs are still in effect.

The Asia Pacific region is expected to hold a significant share of the Erythropoietin drugs market:

The Asia Pacific region is expected to hold a significant share of the erythropoietin drugs market, driven by the rapidly increasing population and the high prevalence of chronic diseases such as cancer and chronic kidney disease (CKD). The region is a promising market for the growth of erythropoietin, and the majority of originator companies for erythropoietin are focusing on the Asia-Pacific market. India and China are major erythropoietin biosimilar markets, and the region demonstrates the largest share of the biosimilar industry, owing to the development of biosimilars by major manufacturers in these regions. The majority of biosimilar manufacturers in Asia-Pacific can afford to launch biosimilar versions of erythropoietin at 25-40% less price than innovator products. The Asia-Pacific and LAMEA regions offer promising growth opportunities for erythropoietin manufacturers as these regions are less explored for erythropoietin.

Key developments:

  • In June 2020, GlaxoSmithKline plc (GSK) secured Japanese regulatory approval for Duvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), in the treatment of anaemia associated with chronic kidney disease (CKD).

Segmentation

By Type

  • Biologics
  • Biosimilars

By Product

  • Erythropoietin
  • Darbepoetin-alfa

By Application

  • Cancer
  • Renal Diseases
  • Neurology
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. ERYTHROPOIETIN DRUGS MARKET, BY TYPE

  • 5.1. Introduction
  • 5.2. Biologics
  • 5.3. Biosimilars

6. ERYTHROPOIETIN DRUGS MARKET, BY PRODUCT

  • 6.1. Introduction
  • 6.2. Erythropoietin
  • 6.3. Darbepoetin-alfa

7. ERYTHROPOIETIN DRUGS MARKET, BY APPLICATION

  • 7.1. Introduction
  • 7.2. Cancer
  • 7.3. Renal Diseases
  • 7.4. Neurology
  • 7.5. Others

8. ERYTHROPOIETIN DRUGS MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

  • 10.1. Mayo Clinic
  • 10.2. Weefsel Pharma
  • 10.3. Trumac Healthcare
  • 10.4. Incepta Pharmaceuticals Ltd.
  • 10.5. FosunPharma
  • 10.6. Rewine Pharmaceuticals
  • 10.7. Kyowa Kirin
  • 10.8. Mircera
  • 10.9. ACRO Biosystems
  • 10.10. Fierce Pharma